VJRegenMed is committed to improving our service to you

Share this video  

VJRegenMed is committed to improving our service to you

Advanced Therapies Week 2022 | The changing landscape of hospital-based cell and gene therapy manufacturing

Greg Roumeliotis, MSc, Orgenesis, Germantown, MD, discusses the evolving space of hospital-based cell and gene therapy (CGT) manufacturing. Cell and gene therapies are being developed very quickly to meet the growing demand in healthcare and there are ongoing efforts to make these therapies more accessible and affordable for patients. Mr Roumeliotis talks on the breadth of the CGT space, as well as promising non-viral vector and allogeneic cell therapies. He additionally highlights the role of Orgenesis in accelerating the manufacturing process of cell and gene therapies, increasing the availability of know-how and technology to stakeholders. This interview took place at Advanced Therapies Week 2022.

Disclosures

Greg Roumeliotis, MSc is an employee of Orgenesis.